Futura Medical plc has announced that James Barder and his spouse, Charlotte Barder, have gifted 20,000 Ordinary Shares to a family member as part of inheritance and tax planning. Following this transaction, James Barder's interests in Ordinary Shares amount to 1,420,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital.
Futura Medical plc, listed on AIM, is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology. The company's breakthrough treatment for erectile dysfunction, MED3000, has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes." Eroxon® is available Over the Counter ("OTC") without a doctor's prescription.
MED3000, now being manufactured and commercialized under the brand name Eroxon®, has been granted marketing authorization by the FDA in the US, CE marked in Europe, UKCA marked in the UK, and is gaining regulatory approval in a growing number of countries across the world. Futura has commercial agreements with Haleon for the US market and Cooper Consumer Health for Europe.
The company is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
The notification also includes details of the person discharging managerial responsibilities (PDMR) and person closely associated (PCA) with the transaction, as well as the nature and details of the transaction.
For further information, contact details for investor relations and media inquiries are provided in the announcement.